iBio
[stock_market_widget type=”inline-label” template=”indicator” assets=”IBIO” realtime=”true” api=”yahoo-finance”]
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”IBIO” fields=”market_cap,enterprise_value,pe_ratio,forward_pe_ratio,peg_ratio,price_to_sales_trailing_12_months,price_book,enterprise_revenue,enterprise_ebitda” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”IBIO” fields=”volume,open,previous_close,range,52_week_range,beta,target_high_price,shares_outstanding,shares_float” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
[stock_market_widget type=”chart” template=”line” assets=”IBIO” range=”1y” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#000000″ range_selector=”true” axes=”true” cursor=”true” style=”font-size: 14px” api=”yahoo-finance”]
Description
iBio uses artificial intelligence and computational biology to discover and develop therapeutic antibodies. Its platform supports oncology, autoimmune, and other disease programs by identifying and optimizing novel biologic candidates.
Financial Highlights
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”IBIO” fields=”profit_margin,operating_margin,return_on_assets,return_on_equity,total_revenue,revenue_per_share,revenue_growth,gross_profit,ebitda,net_income_to_common,quarter_earnings_growth,total_cash,total_cash_per_share,total_debt,operating_cashflow” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
Trading Information
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”IBIO” fields=”52_week_low_change_pct,52_week_high,52_week_low,50_day_average,200_day_average,average_volume,average_volume_10_days,shares_outstanding,shares_float,held_percent_insiders,held_percent_institutions,shares_short,short_ratio,annual_dividend_rate,annual_dividend_yield” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
